Gregor K Wenning Selected Research

Cerebellar Ataxia (Dysmetria)

1/2019	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial.
5/2017	Topography of Dopamine Transporter Availability in the Cerebellar Variant of Multiple System Atrophy.
1/2016	Anle138b Partly Ameliorates Motor Deficits Despite Failure of Neuroprotection in a Model of Advanced Multiple System Atrophy.
1/2015	Models of multiple system atrophy.
1/2013	Multiple system atrophy.
6/2012	Behavioral and histological analysis of a partial double-lesion model of parkinson-variant multiple system atrophy.
8/2010	Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure.
9/2009	Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy.
9/2005	Animal models of multiple system atrophy.
8/2005	Therapeutic strategies in multiple system atrophy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gregor K Wenning Research Topics

Disease

71	Multiple System Atrophy 01/2022 - 08/2003
41	Parkinson Disease (Parkinson's Disease) 10/2021 - 08/2003
23	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2021 - 08/2003
21	Parkinsonian Disorders (Parkinsonism) 01/2020 - 05/2003
16	Synucleinopathies 01/2022 - 09/2009
12	Cerebellar Ataxia (Dysmetria) 01/2019 - 09/2003
7	Disease Progression 01/2019 - 09/2003
6	Neuroinflammatory Diseases 01/2022 - 11/2007
6	Orthostatic Hypotension (Postural Hypotension) 01/2020 - 02/2015
6	Striatonigral Degeneration 10/2015 - 08/2003
5	Movement Disorders (Movement Disorder) 04/2021 - 03/2004
5	Gliosis 01/2020 - 08/2005
4	Olivopontocerebellar Atrophies (Olivopontocerebellar Atrophy) 11/2021 - 03/2005
4	Dementia (Dementias) 10/2020 - 06/2011
3	Psychotic Disorders (Schizoaffective Disorder) 10/2020 - 03/2004
3	Dystonia (Limb Dystonia) 01/2020 - 08/2007
3	Shy-Drager Syndrome 01/2013 - 08/2010
3	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 11/2012 - 08/2006
3	Huntington Disease (Huntington's Disease) 03/2006 - 05/2002
2	Dizziness (Lightheadedness) 01/2020 - 02/2015
2	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 01/2019
2	Hypertension (High Blood Pressure) 01/2020 - 01/2019
2	Proteostasis Deficiencies 01/2019 - 01/2016
2	Autonomic Nervous System Diseases (Dysautonomia) 11/2010 - 03/2005
2	Dystonic Disorders (Writer's Cramp) 08/2007 - 12/2005
2	Torticollis (Wryneck) 08/2007 - 01/2002
1	Prion Diseases (Transmissible Spongiform Encephalopathies) 09/2021
1	Malnutrition (Nutritional Deficiencies) 01/2021
1	Multiple Sclerosis 01/2020
1	Inflammation (Inflammations) 01/2020
1	Dyspnea (Shortness of Breath) 01/2020
1	Lewy Body Disease (Lewy Body Dementia) 01/2020
1	Hypovolemia 01/2020
1	Hypertensive Crisis 01/2020
1	Low Back Pain (Lumbago) 01/2020
1	Cognitive Dysfunction 01/2020
1	Pain (Aches) 01/2020
1	Fatigue 01/2020
1	Syncope (Fainting) 01/2020
1	Respiratory Sounds (Crackle) 10/2019
1	Prodromal Symptoms 01/2019
1	Iron Overload 01/2019
1	Atrophy 01/2018
1	REM Sleep Behavior Disorder 11/2015
1	Urinary Tract Infections (Urinary Tract Infection) 02/2015

Drug/Important Bio-Agent (IBA)

34	SynucleinsIBA 01/2022 - 02/2011
13	Levodopa (L Dopa)FDA LinkGeneric 04/2021 - 09/2003
13	alpha-SynucleinIBA 01/2017 - 08/2003
10	Biomarkers (Surrogate Marker)IBA 04/2021 - 05/2003
6	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 05/2017 - 07/2005
5	CytokinesIBA 01/2020 - 08/2003
5	Pharmaceutical PreparationsIBA 10/2019 - 08/2005
4	rasagiline (Azilect)FDA Link 01/2022 - 04/2008
4	IronIBA 01/2019 - 10/2005
4	serum P-component (CIt)IBA 05/2017 - 04/2011
4	3-nitropropionic acidIBA 05/2012 - 08/2003
4	Riluzole FDA LinkGeneric 01/2006 - 01/2002
3	PrionsIBA 09/2021 - 10/2006
3	hydroxide ionIBA 01/2020 - 03/2016
3	Proteins (Proteins, Gene)FDA Link 08/2015 - 08/2003
3	Amantadine (Aman)FDA LinkGeneric 01/2006 - 03/2004
2	Toll-Like Receptor 4IBA 10/2021 - 01/2017
2	Dronabinol (THC)FDA LinkGeneric 10/2020 - 01/2020
2	Antihypertensive Agents (Antihypertensives)IBA 01/2020 - 04/2016
2	3- (1,3- benzodioxol- 5- yl)- 5- (3- bromophenyl)- 1H- pyrazoleIBA 01/2019 - 01/2016
2	Peroxidase (Myeloperoxidase)IBA 10/2015 - 05/2012
2	Botulinum Toxins (Botulinum Toxin)IBA 08/2007 - 12/2005
2	Dopamine (Intropin)FDA LinkGeneric 09/2006 - 02/2005
2	Pramipexole (Mirapex)FDA LinkGeneric 08/2006 - 01/2006
2	2beta- carbomethoxy- 3beta- (4- iodophenyl)tropane (Iometopane)IBA 08/2006 - 07/2005
2	Mirtazapine (Rexer)FDA LinkGeneric 01/2006 - 03/2004
2	Olanzapine (Zyprexa)FDA Link 01/2006 - 03/2004
2	Neuroprotective AgentsIBA 02/2005 - 10/2004
1	ATH434IBA 11/2021
1	nabilone (Cesamet)FDA Link 10/2020
1	ChemokinesIBA 01/2020
1	SaltsIBA 01/2020
1	Sirolimus (Rapamycin)FDA Link 01/2020
1	CannabidiolIBA 01/2020
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 01/2020
1	SodiumIBA 01/2019
1	Mannitol (Osmitrol)FDA LinkGeneric 01/2019
1	epigallocatechin gallate (epigallocatechin-3-gallate)IBA 01/2019
1	AntibodiesIBA 01/2018
1	Macrophage Colony-Stimulating FactorIBA 01/2018
1	Biological ProductsIBA 01/2018
1	monophosphoryl lipid AIBA 01/2017
1	LipidsIBA 01/2016
1	MicroRNAs (MicroRNA)IBA 01/2016
1	Messenger RNA (mRNA)IBA 01/2016
1	CatecholaminesIBA 08/2015

Therapy/Procedure

12	Therapeutics 01/2022 - 01/2002
3	Transplantation 09/2009 - 12/2005
2	Drug Therapy (Chemotherapy) 01/2022 - 10/2019
1	Gastrostomy 01/2021
1	Institutionalization (Institutionalized Persons) 10/2020
1	Deep Brain Stimulation 10/2020
1	Tracheostomy 10/2019
1	Continuous Positive Airway Pressure 10/2019
1	Immunotherapy 01/2018